Jason A. Efstathiou, MD, DPhil, on Bladder Cancer: What Is the Best Treatment Option?
2019 Genitourinary Cancers Symposium
Jason A. Efstathiou, MD, DPhil, of Massachusetts General Hospital, discusses the debate over treating muscle-invasive bladder cancer with radical cystectomy vs trimodality therapy.
Karim Fizazi, MD, PhD, of the University of Paris-Sud and Gustave Roussy, discusses study findings on the efficacy and safety of darolutamide in men with nonmetastatic castration-resistant prostate cancer (Abstract 140).
Silke Gillessen, MD, of Cantonal Hospital St. Gallen, discusses data from a phase III study on the incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab. The trial was designed to assess prevention of symptomatic skeletal events with denosumab administered every 4 weeks vs every 12 weeks (Abstract 139).
Sumanta K. Pal, MD, of City of Hope, who served as a Co-Executive Editor of the 2019 publication Clinical Cancer Advances, discusses progress made during the past year in research and policy. The report was compiled with a team of experts in oncology subspecialties, cancer prevention, quality care, health disparities, and tumor biology.
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses phase III findings on a comparison of tivozanib and sorafenib in patients with refractory advanced renal cell carcinoma (Abstract 541).
Thomas Powles, MD, PhD, of Queen Mary University of London, discusses phase III study findings on ramucirumab plus docetaxel vs placebo plus docetaxel in patients with advanced platinum-refractory urothelial carcinoma (Abstract 353).
